Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses
- 14 June 2010
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 107 (26), 11895-11899
- https://doi.org/10.1073/pnas.1006500107
Abstract
One half of a group of 20 patients with human papillomavirus type 16 (HPV16)-induced vulvar intraepithelial neoplasia grade 3 displayed a complete regression (CR) after therapeutic vaccination with HPV16 E6/E7 synthetic long peptides. Patients with relatively larger lesions generally did not display a CR. To investigate immune correlates of treatment failure, patients were grouped according to median lesion size at study entry, and HPV16-specific immunity was analyzed at different time points by complementary immunological assays. The group of patients with smaller lesions displayed stronger and broader vaccine-prompted HPV16-specific proliferative responses with higher IFN gamma (P = 0.0003) and IL-5 (P < 0.0001) levels than patients with large lesions. Characteristically, this response was accompanied by a distinct peak in cytokine levels after the first vaccination. In contrast, the patient group with larger lesions mounted higher frequencies of HPV16-specific CD4(+)CD25(+)Foxp3(+)T cells (P = 0.005) and displayed a lower HPV16-specific IFN gamma/IL-10 ratio after vaccination (P<0.01). No disparity in T memory immunity to control antigens was found, indicating that the differences in HPV-specific immunity did not reflect general immune failure. We observed a strong correlation between a defined set of vaccine-prompted specific immune responses and the clinical efficacy of therapeutic vaccination. Notably, a high ratio of HPV16-specific vaccine-prompted effector T cells to HPV16-specificCD4(+)CD25(+)Foxp3(+)T cells was predictive of clinical success. Foxp3(+)T cells have been associated previously with impaired immunity in malignancies. Here we demonstrate that the vaccine-prompted level of this population is associated with early treatment failure.Keywords
This publication has 43 references indexed in Scilit:
- Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor functionJournal of Translational Medicine, 2009
- Surgery followed by Persistence of High-Grade Squamous Intraepithelial Lesions Is Associated with the Induction of a Dysfunctional HPV16-Specific T-Cell ResponseClinical Cancer Research, 2008
- Human Leukocyte Antigen Class I, MHC Class I Chain-Related Molecule A, and CD8+/Regulatory T-Cell Ratio: Which Variable Determines Survival of Cervical Cancer Patients?Clinical Cancer Research, 2008
- Adoptive cell transfer: a clinical path to effective cancer immunotherapyNature Reviews Cancer, 2008
- Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides VaccineClinical Cancer Research, 2008
- Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA‐DQ and –DP as a restriction elementInternational Journal of Cancer, 2007
- T cells stimulated in vitro have a suppressive function but do not contain only regulatory T cellsClinical and Experimental Immunology, 2007
- Association of cervical cancer with the presence of CD4+regulatory T cells specific for human papillomavirus antigensProceedings of the National Academy of Sciences, 2007
- Transient regulatory T-cells: A state attained by all activated human T-cellsClinical Immunology, 2006
- Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patientsGynecologic Oncology, 2005